Preventing Organ Transplant Rejection: Immunosuppressive Regimens and Monitoring
Transplant rejection occurs when the recipient's immune system recognizes donor HLA antigens as foreign. Lifelong immunosuppression is the cornerstone of prevention, balanced against infection and malignancy risks.
Induction Therapy (Peri-transplant, High-Intensity)
- IL-2 Receptor Antagonists (Basiliximab): Blocks IL-2R on activated T-cells; low side-effect profile; used in low-immunologic-risk kidney/pancreas transplants.
- Depleting Antibodies (Thymoglobulin/ATG, Alemtuzumab): Lymphocyte depletion; reserved for high-risk recipients (retransplant, high PRA, ABO-incompatible).
Maintenance Immunosuppression (Triple Therapy Standard)
| Class | Agents | Mechanism | Key Monitoring |
|---|---|---|---|
| Calcineurin Inhibitors (CNI) | Tacrolimus (Tac), Cyclosporine (CsA) | Block IL-2 transcription → T-cell activation | Trough levels, renal function, glucose, BP, neurotoxicity |
| Antiproliferatives | Mycophenolate (MMF/MPA), Azathioprine | Inhibit purine synthesis → lymphocyte proliferation | CBC (leukopenia, anemia), GI, LFTs |
| Corticosteroids | Prednisone | Broad anti-inflammatory, genomic effects | Glucose, bone density, cataracts, weight, infection |
Newer/Adjunct Agents
- mTOR inhibitors (Sirolimus, Everolimus): CNI-sparing, anti-neoplastic; risks include wound healing impairment, hyperlipidemia, proteinuria.
- Belatacept (CTLA4-Ig): Costimulation blocker; IV monthly; better renal function but higher early acute rejection; contraindicated in EBV-negative patients.
- JAK inhibitors (Tofacitinib): Emerging for refractory rejection.
Rejection Types & Treatment
- Acute Cellular Rejection (ACR): T-cell mediated; biopsy-proven; treat with pulse steroids ± thymoglobulin.
- Antibody-Mediated Rejection (AMR): Donor-specific antibodies (DSA) + C4d + histology; treat with plasmapheresis, IVIG, rituximab, bortezomib, eculizumab.
- Chronic Rejection: Fibrosis, vasculopathy; limited reversibility; optimize maintenance, consider retransplant.
Monitoring & Long-Term Care
- Protocol biopsies (kidney) or surveillance (heart: gene expression, echo; lung: bronchoscopy).
- DSA monitoring (single antigen beads).
- Cancer screening (skin, PTLD, cervical), cardiovascular risk reduction, bone health, vaccination (inactivated pre-transplant; live contraindicated).
Individualized regimens, therapeutic drug monitoring, and multidisciplinary care optimize graft survival.
Kidney Disease - Related Articles
- Preventing Uric Acid Kidney Stones: Diet & Lifestyle Strategies
- What the Kidneys Filter: Comprehensive List of Substances
- Understanding End-Stage Renal Disease (ESRD): Causes, Symptoms & Management
- Mental Health and Kidney Stones: Exploring Potential Links
- Prevent Kidney Decline: A Dietary Guide for Optimal Health
- Car Paint and Kidney Health: Risks & Prevention for Auto Body Professionals
- Alcohol's Effects on Kidney Function: Dehydration, Electrolytes, and Chronic Damage
